This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Spironolactone and ACEI or ARBs - safety advice

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Reminder for healthcare professionals:

  • concomitant use of spironolactone with ACEi or ARB is not routinely recommended because of the risks of severe hyperkalaemia, particularly in patients with marked renal impairment

  • use the lowest effective doses of spironolactone and ACEi or ARB if coadministration is considered essential

  • regularly monitor serum potassium levels and renal function

  • interrupt or discontinue treatment in the event of hyperkalaemia

Reference:

  • Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update February 2016.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.